1 / 1

Nivolumab and Relatlimab(Opdualag)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Bristol-Myers Squibb

Formulation:

SOLUTION

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Opdualag(Nivolumab and Relatlimab) Instructions:Uses,Dosage, Side Effects

OPDUALAG is a fixed-dose combination biologic therapy for intravenous use, comprising two distinct monoclonal antibodies: nivolumab, which targets the PD-1 receptor, and relatlimab, which targets the LAG-3 receptor. This dual-immunotherapy approach is designed to enhance T-cell-mediated anti-tumor immune responses. The product is supplied as a sterile, preservative-free solution in a single-dose vial and must be stored refrigerated. It is manufactured by Bristol-Myers Squibb and is indicated specifically for a defined patient population with advanced melanoma.

Generic name

Nivolumab and Relatlimab(Opdualag)

English name

Nivolumab and Relatlimab

Alternative Names

Opdualag

Drug prices

Indications

OPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable oOPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. The safety and efficacy in pediatric patients under 12 years of age, or those 12 years and older weighing less than 40 kg, have not been established.r metastatic melanoma. The safety and efficacy in pediatric patients under 12 years of age, or those 12 years and older weighing less than 40 kg, have not been established.

Therapeutic Target

LAG3xPD-1

Active Ingredients

Nivolumab and Relatlimab

Dosage form

SOLUTION

specifications

20ml * 1 bottle/box

Description

Dosage and Administration

480 mg nivolumab and 160 mg relatlimab administered via intravenous infusion every 4 weeks.

CATEGORY NAVIGATION